Current Report Filing (8-k)
August 05 2019 - 3:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 5, 2019
Eloxx Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-31326
|
|
84-1368850
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
950 Winter Street
Waltham, MA
|
|
02451
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(Registrant’s telephone number, including
area code): (781) 577-5300
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.01 par value per share
|
ELOX
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On August 5, 2019, Eloxx Pharmaceuticals, Inc. (the
“Company”) issued a press release announcing, among other things, the initiation of a phase 2 clinical trial of
ELX-02 in cystinosis in Canada, as well as information regarding the Company’s webcast and conference call on August 7,
2019 at 8:30 am ET to report second quarter 2019 financial results and provide a business update. A copy of the press release
is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELOXX PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Gregory Weaver
|
|
Name:
|
Gregory Weaver
|
|
Title:
|
Chief Financial Officer
|
Date: August 5, 2019
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From May 2024 to Jun 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Jun 2023 to Jun 2024